ID
28252
Description
NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Visit: Cycle 1, Day 1. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz
Keywords
Versions (3)
- 11/30/17 11/30/17 -
- 12/7/17 12/7/17 -
- 12/31/17 12/31/17 -
Copyright Holder
Prof. Dr. med. Georg Heß
Uploaded on
December 31, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Vital signs Day 1/2 GOAL Trial B-cell Lymphoma NCT02499003
Vital signs Day 1/2 GOAL Trial B-cell Lymphoma NCT02499003
- StudyEvent: ODM
Similar models
Vital signs Day 1/2 GOAL Trial B-cell Lymphoma NCT02499003
- StudyEvent: ODM
No comments